MDCE Launches Melanoma Scan AI Beta

Medical Care Technologies (OTC: MDCE) enters advanced internal beta for its AI-powered melanoma scan imaging platform, advancing its skin cancer health tech strategy with a longitudinal body-map tracking system.

Lead

What Happened

MDCE entered the current beta phase with a defined set of evaluation benchmarks: platform stability, workflow performance, image management functionality, interface responsiveness, and image consistency processing. The internal testing cycle is designed to stress-test infrastructure before any broader rollout.

The MDCE Melanoma Scan platform has been in iterative development, with the company disclosing additional platform details in late May before transitioning into live testing in June. Each communication has emphasized the platform's role as an image organization and longitudinal monitoring system rather than a diagnostic device.

The Platform

At its core, MDCE Melanoma Scan is structured around an interactive body-map interface that allows users to assign and archive skin images to specific anatomical locations. The system is designed to support long-term visual tracking by enabling direct comparison of images captured at different points in time — a workflow aimed at helping users identify visible changes in skin appearance over extended periods.

The platform's architecture prioritizes a low-friction user experience, centralizing image organization, navigation, and historical record review within a single environment. Development focus has been placed on building a structured longitudinal imaging framework that clinicians or users can leverage to maintain organized image histories alongside timeline comparisons.

Regulatory Position

MDCE has been explicit in framing the platform's current boundaries: the MDCE Melanoma Scan Beta has not been reviewed or cleared by the U.S. Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. The company positions the product as an image management and monitoring application rather than a clinical decision-support or diagnostic tool at this stage, a distinction that shapes its development pathway and near-term commercialization strategy.

Strategic Context

MDCE's melanoma scan initiative arrives as institutional and clinical interest in AI-assisted skin cancer detection has grown substantially. Research published in 2026 indicates that AI models trained on datasets exceeding 400,000 dermatological images can match or approach dermatologist-level sensitivity and specificity when evaluating suspicious lesions — a data point that underscores the commercial and clinical rationale for the category. Studies further suggest the combination of AI support with dermoscopy delivers the highest diagnostic performance, though equitable performance across diverse skin tones remains an active challenge across the industry.

AI and Technology Angle

The melanoma AI sector has attracted growing corporate and research investment, with developers ranging from early-stage OTC-listed companies to large medical device incumbents and academic spinouts all advancing imaging and detection tools. MDCE's approach — focusing first on image management infrastructure and body-map organization — positions the platform as a workflow layer that could later integrate more advanced analytical capabilities once regulatory pathways are navigated.

Consumer-facing skin cancer health tech applications have increasingly targeted the gap between annual dermatologist visits, with platforms designed to allow individuals and primary care providers to maintain consistent visual records of skin lesions between appointments. MDCE's beta product addresses this gap without requiring immediate FDA clearance, a strategy that accelerates time-to-market while deferring diagnostic claims.

Outlook

Technology